CN109260207A - 嘧啶二酮衍生物化合物的制剂 - Google Patents

嘧啶二酮衍生物化合物的制剂 Download PDF

Info

Publication number
CN109260207A
CN109260207A CN201811208736.2A CN201811208736A CN109260207A CN 109260207 A CN109260207 A CN 109260207A CN 201811208736 A CN201811208736 A CN 201811208736A CN 109260207 A CN109260207 A CN 109260207A
Authority
CN
China
Prior art keywords
pharmaceutical composition
polymer
compound
salt
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811208736.2A
Other languages
English (en)
Chinese (zh)
Inventor
李艳霞
高坪
石屹
H.侯
M.麦卡普罗
K.A.米多斯
G.G.张
高忆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CN109260207A publication Critical patent/CN109260207A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201811208736.2A 2012-10-18 2013-10-18 嘧啶二酮衍生物化合物的制剂 Pending CN109260207A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261715766P 2012-10-18 2012-10-18
US61/715766 2012-10-18
CN201380066499.XA CN104853752B (zh) 2012-10-18 2013-10-18 嘧啶二酮衍生物化合物的制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380066499.XA Division CN104853752B (zh) 2012-10-18 2013-10-18 嘧啶二酮衍生物化合物的制剂

Publications (1)

Publication Number Publication Date
CN109260207A true CN109260207A (zh) 2019-01-25

Family

ID=49554481

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811208736.2A Pending CN109260207A (zh) 2012-10-18 2013-10-18 嘧啶二酮衍生物化合物的制剂
CN201380066499.XA Expired - Fee Related CN104853752B (zh) 2012-10-18 2013-10-18 嘧啶二酮衍生物化合物的制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380066499.XA Expired - Fee Related CN104853752B (zh) 2012-10-18 2013-10-18 嘧啶二酮衍生物化合物的制剂

Country Status (11)

Country Link
US (2) US9629841B2 (US07981874-20110719-C00313.png)
EP (1) EP2908808A1 (US07981874-20110719-C00313.png)
JP (2) JP6266635B2 (US07981874-20110719-C00313.png)
CN (2) CN109260207A (US07981874-20110719-C00313.png)
AU (1) AU2013330993B2 (US07981874-20110719-C00313.png)
BR (1) BR112015008927A2 (US07981874-20110719-C00313.png)
CA (1) CA2888883A1 (US07981874-20110719-C00313.png)
EA (2) EA032913B1 (US07981874-20110719-C00313.png)
MX (1) MX2015004973A (US07981874-20110719-C00313.png)
SG (1) SG11201503051QA (US07981874-20110719-C00313.png)
WO (1) WO2014063101A1 (US07981874-20110719-C00313.png)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
MX2022011058A (es) * 2020-03-05 2022-12-13 Aurigene Discovery Tech Ltd Composiciones farmaceuticas de un inhibidor de cinasa.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009039134A1 (en) * 2007-09-17 2009-03-26 Abbott Laboratories Anti-infective pyrimidines and uses thereof
CN101801935A (zh) * 2007-09-17 2010-08-11 雅培制药有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4442257A1 (de) * 1994-11-28 1996-05-30 Beate Dr Podschun Sparsomycin
ES2277682T3 (es) 1998-06-11 2007-07-16 PHARMACIA & UPJOHN COMPANY LLC Formulacion de delavirdina en comprimido.
SK8562002A3 (en) 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
KR20070116581A (ko) * 2004-12-15 2007-12-10 엘란 파마 인터내셔널 리미티드 나노입자형 타크롤리무스 제제
US20070082952A1 (en) * 2005-10-06 2007-04-12 Benjamin Eric J Pharmaceutical compositions, methods of preparation thereof, and methods of treatment
US20100166861A1 (en) * 2008-12-29 2010-07-01 Kelly Noel Lynch Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
EP2542075A4 (en) * 2010-03-01 2014-11-05 Concert Pharmaceuticals Inc Fluorouracil DERIVATIVES
MX2014004729A (es) * 2011-10-21 2014-07-28 Abbvie Inc Tratamiento en combinacion (por ejemplo, con abt-072 o abt-333) de agentes antivirales de accion directa para utilizarse en el tratamiento del virus de la hepatitis c.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009039134A1 (en) * 2007-09-17 2009-03-26 Abbott Laboratories Anti-infective pyrimidines and uses thereof
CN101801935A (zh) * 2007-09-17 2010-08-11 雅培制药有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物

Also Published As

Publication number Publication date
EA201791354A3 (ru) 2018-03-30
EP2908808A1 (en) 2015-08-26
MX2015004973A (es) 2015-07-17
US9629841B2 (en) 2017-04-25
EA028481B1 (ru) 2017-11-30
WO2014063101A1 (en) 2014-04-24
AU2013330993A1 (en) 2015-05-07
CN104853752B (zh) 2018-10-23
CN104853752A (zh) 2015-08-19
EA201590752A1 (ru) 2016-02-29
EA201791354A2 (ru) 2017-11-30
SG11201503051QA (en) 2015-05-28
JP2018065858A (ja) 2018-04-26
BR112015008927A2 (pt) 2017-07-04
AU2013330993B2 (en) 2018-03-01
EA032913B1 (ru) 2019-08-30
JP2015534985A (ja) 2015-12-07
US20170181973A1 (en) 2017-06-29
US20140113921A1 (en) 2014-04-24
CA2888883A1 (en) 2014-04-24
US10201542B2 (en) 2019-02-12
JP6266635B2 (ja) 2018-01-24

Similar Documents

Publication Publication Date Title
JP6932746B2 (ja) エンザルタミドの製剤
ES2256544T3 (es) Comprimidos de tamsulosina.
AU2007356942B2 (en) Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
CA2715802A1 (en) Pharmaceutical composition for poorly soluble drugs
JP2008531509A (ja) 医薬品成分の改良された分散性を有する錠剤
JP2022548687A (ja) Ｔｙｋ２阻害薬の剤形
US10201542B2 (en) Formulations of pyrimidinedione derivative compounds
US8987285B2 (en) Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
ES2321908T3 (es) Preparaciones farmaceuticas de liberacion prolongada independientemente del ph.
WO2009043914A1 (en) Multi particulate matrix system containing galantamine
US20130165459A1 (en) Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
JP4842960B2 (ja) 低水溶性薬物とともに使用することによく適した圧縮固体状投与形態の製造方法およびそれにより製造された圧縮固体状投与形態
WO2024043842A1 (en) Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients
WO2024095296A1 (en) Solvent free solid oral composition of bcs class iv drugs
CA2174538A1 (en) Base for sustained-release preparation, sustained-release preparation, and process for producing the preparation
WO2019030773A1 (en) DICLOFENAC COMPOSITIONS WITH LOW DOSE

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190125

WD01 Invention patent application deemed withdrawn after publication